Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · Real-Time Price · USD
4.850
-0.300 (-5.83%)
At close: May 15, 2026, 4:00 PM EDT
4.900
+0.050 (1.03%)
After-hours: May 15, 2026, 7:00 PM EDT

Atossa Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-37.64-34.77-25.5-30.09-26.96-20.61
Depreciation & Amortization
0.020.020.020.020.010.02
Stock-Based Compensation
2.812.652.294.626.795.27
Other Adjustments
--1.722.990-
Changes in Accounts Payable
1.43.61-0.13-2.161.250.13
Changes in Accrued Expenses
1.020.39-0.05-0.090.860.11
Changes in Other Operating Activities
-0.99-1.660.633.76-2.7-1.4
Operating Cash Flow
-33.38-29.76-21.03-20.94-20.76-16.47
Capital Expenditures
-0.01-0.02-0.02-0.01-0.03-0.01
Purchases of Investments
-----4.7-
Investing Cash Flow
-0.01-0.02-0.02-0.01-4.73-0.01
Issuance of Common Stock
--3.67--113.88
Repurchase of Common Stock
----1.48--0.57
Net Common Stock Issued (Repurchased)
--3.67-1.48-113.3
Financing Cash Flow
--3.67-1.48-113.3
Net Cash Flow
-33.4-29.79-17.38-22.43-25.4996.82
Free Cash Flow
-33.4-29.79-21.05-20.96-20.79-16.48
Free Cash Flow Per Share
-3.88-3.46-2.51-2.49-2.46-2.11
Levered Free Cash Flow
-36.2-32.43-25.06-28.57-27.58-21.75
Unlevered Free Cash Flow
-38.16-34.8-27.18-29.85-28.31-21.66
Updated May 8, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q